Cutterguide: No Printing Process: Offset, GD: ZS 39603
Size: 195 X 125 mm Pages: 16 Colors: C M Y K (4 Colors), Native File: Indesign CC Windows Generated in: Acrobat Distiller XI
Doctors and HIV consultants/nurses can request additional brochures from GSK/ViiV Healthcare. TRIUMEQ® (dolutegravir/abacavir/lamivudine) This medicinal product is subject to additional monitoring. Triumeq is indicated for the treatment of adults and adolescents above 12 years of age weighing at least 40 kg who are infected with human Immunodeficiency virus (HIV). Before initiating treatment with Triumeq screening for carriage of the HLA-B*5701 allele should be performed.
(doluteg gra avirr/a abacavir/lamivudine)
Triumeq must not be given if you are allergic to dolutegravir, abacavir, lamivudine or any of the excipients in Triumeq or if you are taking dofetilide, a medicine for disturbances of heart rhythm, as it may cause serious side effects. If you believe this is applicable for you - contact your doctor. Do not drive or operate machinery if you feel dizzy or experience other types of adverse events that can have impact on your ability to drive or operate machinery. Read the package leaflet thoroughly before you use Triumeq. If you want to report an adverse event to any of our medicines or vaccines please contact us by one of the following ways: Web form: se.gsk.com/biverkning Phone: + 46 8 638 93 00 (ask to be connected to Pharmacovigilance) DATE OF PREPARATION: DECEMBER 2015
SE/TRIM/0015/15
GSK, BOX 516, 169 29 SOLNA. TFN. 08-638 93 00 SE.GSK.COM, INFO.PRODUKT@GSK.COM TRIUMEQ is a registered trademark of the ViiV Healthcare Group of Companies. ©2015 ViiV Healthcare group of companies All rights reserved.
SETRIM001515_Triumeq_Brochure_GSKDC-PT-SCD-2015-0384_D2.indd 1-2
PATI ENT IN FORMATION
1/19/2016 1:37:43 PM